Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

被引：0
|
作者：
Laura Obici
Senda Ajroud-Driss
Kon-Ping Lin
John L. Berk
Julian D. Gillmore
Parag Kale
Haruki Koike
David Danese
Emre Aldinc
Chongshu Chen
John Vest
David Adams
机构：
[1] IRCCS Fondazione Policlinico San Matteo,Amyloidosis Research and Treatment Centre
[2] Northwestern University Feinberg School of Medicine,Department of Neurology
[3] Taipei Veterans General Hospital,Department of Neurology
[4] Boston Medical Center,National Amyloidosis Centre, Royal Free Hospital
[5] University College London,Department of Neurology
[6] Baylor University Medical Center,Neurology Department
[7] Nagoya University Graduate School of Medicine,undefined
[8] Alnylam Pharmaceuticals,undefined
[9] Université Paris-Saclay,undefined
[10] U1195,undefined
[11] INSERM,undefined
[12] AP-HP,undefined
[13] CHU Bicêtre,undefined
来源：
Neurology and Therapy | 2023年 / 12卷 / 5期
关键词：
ATTRv amyloidosis; hATTR amyloidosis; Nutritional status; Physical function; Polyneuropathy; Quality of life; RNA interference; Vutrisiran;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1759 / 1775
页数：16
相关论文
共 50 条
  • [1] Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
    Obici, Laura
    Ajroud-Driss, Senda
    Lin, Kon-Ping
    Berk, John L.
    Gillmore, Julian D.
    Kale, Parag
    Koike, Haruki
    Danese, David
    Aldinc, Emre
    Chen, Chongshu
    Vest, John
    Adams, David
    NEUROLOGY AND THERAPY, 2023, 12 (05) : 1759 - 1775
  • [2] HELIOS-A: IMPACT OF VUTRISIRAN ON QUALITY OF LIFE AND FUNCTIONAL STATUS IN HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
    Ajroud-Driss, Senda
    Berk, John
    Adams, David
    Gillmore, Julian D.
    Lin, Kon-Ping
    Kale, Parag
    Koike, Haruki
    Aldinc, Emre
    Chen, Chongshu
    Vest, John
    Obici, Laura
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2022, 27 : S6 - S6
  • [3] Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
    Adams, David
    Tournev, Ivailo L.
    Taylor, Mark S.
    Coelho, Teresa
    Plante-Bordeneuve, Violaine
    Berk, John L.
    Gonzalez-Duarte, Alejandra
    Gillmore, Julian D.
    Low, Soon-Chai
    Sekijima, Yoshiki
    Obici, Laura
    Chen, Chongshu
    Badri, Prajakta
    Arum, Seth M.
    Vest, John
    Polydefkis, Michael
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2023, 30 (01): : 18 - 26
  • [4] Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Garcia-Pavia, Pablo
    Grogan, Martha
    Kale, Parag
    Berk, John L.
    Maurer, Mathew S.
    Conceicao, Isabel
    Di Carli, Marcelo
    Solomon, Scott D.
    Chen, Chongshu
    Yureneva, Elena
    Vest, John
    Gillmore, Julian D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (02) : 397 - 410
  • [5] Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Merkel, Madeline
    Danese, David
    Chen, Chongshu
    Wang, Jessie
    Wu, Aozhou
    Yang, Hongbo
    Lin, Hollis
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (10) : 1205 - 1214
  • [6] A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Olatunji, Gbolahan
    Kokori, Emmanuel
    Abraham, Israel Charles
    Omoworare, Oluwatobi
    Olatunji, Doyin
    Ezeano, Chimezirim
    Emmanuel Adeoba, Babawale
    Stanley, Anthony Chidera
    Oluwatobiloba, Awoyinfa Michael
    Oluwademilade, Omidiran Basit
    Shimelis, Kale Mekoya
    Olanisa, Olawale
    Aderinto, Nicholas
    MEDICINE, 2024, 103 (26) : e38767
  • [7] HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Adams, David
    Tournev, Ivailo
    Taylor, Mark
    Coelho, Teresa
    Plante-Bordeneuve, Violaine
    Berk, John
    Gonzalez-Duarte, Alejandra
    Gillmore, Julian
    Low, Soon-Chai
    Sekijima, Yoshiki
    Obici, Laura
    Blakesley, Rick
    Arum, Seth
    Shilling, Rebecca
    Vest, John
    Polydefkis, Michael
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2021, 26 (03) : 309 - 309
  • [8] Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis
    Antunes, Bernardo
    Conceicao, Isabel
    de Campos, Catarina Falcao
    de Carvalho, Mamede
    NEUROLOGICAL SCIENCES, 2025, 46 (02) : 929 - 934
  • [9] Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (02) : 95 - 99
  • [10] Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Gorevic, Peter
    Franklin, Jaclyn
    Chen, Jihong
    Sajeev, Gautam
    Wang, Jessie C. H.
    Lin, Hollis
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (01) : 121 - 129
12345